An Expert Report on AK3280: Development, Mechanism, and Clinical Evaluation

I. Introduction to AK3280

A. Overview of AK3280 as an Investigational Antifibrotic Agent

AK3280 has emerged as a novel, next-generation, orally bioavailable small molecule drug candidate with broad-spectrum anti-fibrotic properties. Its primary clinical development focus is the treatment of Idiopathic Pulmonary Fibrosis (IPF), a debilitating and progressive lung disease.[1] AK3280 is an optimized derivative of pirfenidone, an existing therapeutic agent for IPF. This optimization was aimed at enhancing pharmacological and pharmacokinetic (PK) profiles, achieving superior anti-fibrotic efficacy, and notably, improving the tolerability profile, particularly concerning gastrointestinal side effects and other toxicities associated with current IPF treatments.[1]

Idiopathic Pulmonary Fibrosis represents a significant global health challenge. It is a chronic, progressive, and irreversible interstitial lung disease characterized by the relentless fibrotic remodeling of lung tissue, which ultimately leads to respiratory failure and death.[1] The prognosis for IPF patients is grim, with a median survival period of only 2–5 years following diagnosis. Current approved therapies, pirfenidone and nintedanib, primarily function by slowing the rate of decline in lung function. However, their efficacy is limited, and they are frequently associated with significant adverse effects, such as gastrointestinal disturbances and hepatotoxicity, which can lead to poor long-term tolerability and treatment discontinuation.[1] This therapeutic gap highlights an urgent and substantial unmet medical need for novel, more effective, and better-tolerated treatments for IPF.

B. Addressing the "AK3280 Cream" Query

The specific request for information pertaining to "AK3280 Cream" necessitates a careful examination of the available data. The predominant body of research provided for this report (covering preclinical studies, pharmacokinetic evaluations, and Phase I/II clinical trials) describes AK3280 as an orally administered small molecule intended for systemic fibrotic conditions, with IPF being the lead indication.[1]

Preclinical investigations have demonstrated that AK3280 possesses antifibrotic activity in animal models of skin fibrosis.[3] However, the route of administration employed in these specific skin fibrosis models (e.g., topical application versus systemic administration) is not consistently or explicitly detailed in the provided documentation. Throughout the available materials, AK3280 is consistently characterized by its oral bioavailability.[3]

It is important to note that references to "delgocitinib cream" [14] and "PAC-14028 cream" [15] appear in the research material; however, these are distinct pharmaceutical entities and are not formulations of AK3280. Their presence is likely attributable to keyword associations rather than direct relevance to AK3280's formulation.

Based on a thorough review of the provided research snippets, there is no direct evidence to support the active development, clinical investigation, or current existence of an "AK3280 Cream" formulation. While one database lists "Cicatrix" and "Cicatrix, Hypertrophic" as inactive indications for an AK-3280 compound [16], which could theoretically involve topical treatment, no details regarding such a formulation or its development are provided. The primary and overwhelmingly supported developmental focus for AK3280 is an oral formulation for IPF. The potential for a topical formulation, while perhaps inferable from preclinical skin fibrosis activity, is not substantiated as an active development program within the scope of the provided information.

C. Therapeutic Rationale and Potential Significance

The therapeutic rationale for AK3280 is centered on its potential to offer a superior treatment option for IPF. This is based on its reported capacity to not only slow the decline in lung function but to potentially improve Forced Vital Capacity (FVC) from baseline, as observed in Phase II clinical studies.[1] Coupled with this enhanced efficacy is a significantly improved safety and tolerability profile, particularly a reduction in gastrointestinal side effects that plague current standard-of-care treatments.[1] Furthermore, the broad-spectrum antifibrotic activity demonstrated in various preclinical organ fibrosis models (pulmonary, hepatic, cardiac, skin) suggests that AK3280 may hold promise for a wider range of fibrotic diseases beyond IPF.[1]

II. Drug Identity and Physicochemical Properties

The precise identification of an investigational compound is critical. For AK3280, some ambiguities exist in the provided literature regarding its exact chemical identifiers, potentially reflecting different stages of development or variations in database entries.

A. Nomenclature

• Primary Investigational Name: AK3280 is the most consistently used identifier in recent clinical development for IPF by Ark Biosciences.[1]
• Synonyms/Alternative Codes: Several other codes and names appear, often associated with earlier development stages or specific database entries. These include GDC-3280 (frequently linked to Genentech's initial Phase I studies) [13], RG-6069 [24], AK-3280T [16], AK3287 [29], and AKEX0011.[29]

B. Chemical Identifiers and Structure

A notable discrepancy exists in the CAS Registry Numbers, molecular formulas, and molecular weights reported across different sources. This may indicate an evolution of the compound or data entry variations.

• Identity Associated with AK3280/RG-6069 (Prioritized for current IPF development):
• CAS Registry Number: 1799412-33-1.[16]
• Molecular Formula: C19​H15​F3​N4​O2​.[16]
• Molecular Weight: Approximately 388.34 - 388.35 g/mol.[24]
• Chemical Name [25]: 1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethoxy)phenyl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one.
• Alternative Identity (often associated with GDC-3280/AK3287/AKEX0011):
• CAS Registry Number: 1590403-33-0.[29]
• Molecular Formula: C18​H14​F3​N5​O2​.[29]
• Molecular Weight: Approximately 389.33 g/mol.[29]

The information consistently linking AK3280 to CAS 1799412-33-1 and the C19​H15​F3​N4​O2​ formula in the context of Ark Biosciences' IPF program suggests this is the most relevant identity for the current clinical candidate. The discrepancy should be noted, as it could signify distinct analogues or an evolution in the lead compound structure during its development history from Genentech to ArkBio.

C. Drug Class

AK3280 is classified as a small molecule and an antifibrotic agent.[1] It is specifically identified as a derivative based on the phenyl pyridone chemical scaffold of pirfenidone.[7] Some sources also list it under hepatoprotectants.[18]

D. Developer(s) and Originator

• Originator: Genentech, Inc..[16]
• Current Developer (for IPF): Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) is advancing the clinical development of AK3280 for IPF, having licensed the compound from Roche/Genentech in September 2018.[1]

E. Solubility and Storage

• Solubility:
• GDC-3280 (CAS 1590403-33-0): Reported as soluble in DMSO at 31.25 mg/mL (80.27 mM) with the aid of ultrasonic energy and warming to 60°C. It is noted that hygroscopic DMSO can significantly affect product solubility, and newly opened DMSO is recommended.[29]
• AK3280 (CAS 1799412-33-1): Soluble at 10 mM in DMSO.[24]
• Storage Conditions:
• Powder: Recommended storage at -20°C for up to 3 years, or at 4°C for up to 2 years.[30]
• In Solvent (e.g., DMSO): Recommended storage at -80°C for up to 6 months, or at -20°C for up to 1 month.[29]

Table 1: AK3280 Drug Identity and Physicochemical Properties

Property	Details	Snippet ID(s)
Primary Investigational Name	AK3280	1
Key Aliases	GDC-3280, RG-6069, AK-3280T, AK3287, AKEX0011	13
CAS Number (Primary, for AK3280/RG-6069)	1799412-33-1	16
Molecular Formula (Primary)	C19​H15​F3​N4​O2​	16
Molecular Weight (Primary)	~388.34-388.35 g/mol	24
Chemical Name (Presumed for AK3280)	1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethoxy)phenyl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one	25
CAS Number (Alternative, for GDC-3280/AK3287)	1590403-33-0	29
Molecular Formula (Alternative)	C18​H14​F3​N5​O2​	29
Molecular Weight (Alternative)	~389.33 g/mol	29
Drug Class	Small molecule, Antifibrotic, Phenyl pyridone derivative	7
Originator	Genentech, Inc.	16
Current Developer (IPF)	Ark Biosciences (Shanghai Ark Biopharmaceutical Co., Ltd.)	1
Key Solubility	AK3280: 10 mM in DMSO. GDC-3280: 31.25 mg/mL (80.27 mM) in DMSO (with heat/sonication).	24
Storage (Powder)	-20°C (3 years); 4°C (2 years)	30
Storage (In Solvent)	-80°C (6 months); -20°C (1 month)	29

This table consolidates the key identification parameters for AK3280, transparently presenting the discrepancies found in the source materials regarding CAS numbers and molecular formulas. For a compound in clinical development, precise identification is paramount, and acknowledging such variations is crucial for an accurate scientific report. The data suggests that CAS 1799412-33-1 and formula C19​H15​F3​N4​O2​ are most consistently associated with the AK3280 candidate being advanced by ArkBio for IPF.

III. Mechanism of Action

A. Broad-Spectrum Antifibrotic Agent Optimized from Pirfenidone

AK3280 is consistently characterized as a next-generation, orally bioavailable, broad-spectrum anti-fibrotic small molecule.[1] It was derived through optimization of the chemical structure of pirfenidone, an established treatment for IPF, with the explicit goals of enhancing anti-fibrotic activity, improving pharmacological and pharmacokinetic properties, and achieving superior tolerability.[1]

B. Modulation of Key Fibrotic Pathways and Cellular Effects

The mechanism of action of AK3280 involves the modulation of multiple pathways and biomarkers that are intimately associated with the pathogenesis of fibrosis.[5] Preclinical studies have shown that AK3280 can inhibit the expression of critical fibrosis-related genes and proteins. These include genes such as Col1a1, Col1a2, Col3a1 (encoding various collagen types, which are principal components of the fibrotic scar), and Acta2 (encoding α-smooth muscle actin, a key marker of myofibroblast differentiation and activation). The induction of these genes by potent pro-fibrotic stimuli, including Transforming Growth Factor-beta (TGF-β) and Lysophosphatidic Acid (LPA), was shown to be attenuated by AK3280 in cell-based assays.[5]

At the cellular level, AK3280 exerts its anti-fibrotic effects by reducing the proliferation of fibroblasts, which are the primary cell type responsible for excessive ECM deposition in fibrotic tissues. Furthermore, it inhibits the synthesis and accumulation of ECM components, thereby directly addressing the hallmark pathological feature of fibrosis.[5]

C. Potential Involvement of ASK1-p38 MAPK Pathway

While often described through its relationship to pirfenidone and its broad modulatory effects on fibrotic pathways, some evidence points towards a more specific molecular target for AK3280. Certain sources, often referring to AK3280 by its aliases GDC-3280, AK3287, or AKEX0011, suggest that its mechanism may involve the inhibition of the Apoptosis Signal-regulating Kinase 1 (ASK1) - p38 Mitogen-Activated Protein Kinase (MAPK) signaling pathway.[24] This particular mechanism was observed in the context of AK3280 alleviating inflammatory and fibrotic reactions in a mouse model of silicosis, where it also appeared to regulate macrophage polarization.[24]

The ASK1-p38 MAPK pathway is a critical intracellular signaling cascade that responds to a variety of extracellular and intracellular stress signals, including oxidative stress, endoplasmic reticulum (ER) stress, and inflammatory cytokines. Activation of this pathway plays a significant role in mediating inflammation, apoptosis, and tissue fibrosis. If AK3280 indeed exerts a more potent or specific inhibitory effect on the ASK1-p38 MAPK pathway compared to pirfenidone (whose mechanism is considered pleiotropic and not fully elucidated), this could provide a molecular basis for its reported "enhanced anti-fibrotic activity" [1] and its efficacy across different preclinical models of fibrosis affecting various organs. A more defined target like the ASK1-p38 MAPK pathway could also pave the way for more targeted therapeutic strategies, patient selection, and the development of relevant pharmacodynamic biomarkers.

IV. Non-Clinical Pharmacology

Preclinical studies have been instrumental in characterizing the antifibrotic potential and breadth of activity of AK3280.

A. Broad Antifibrotic Activity in Diverse Animal Models

AK3280 has demonstrated significant antifibrotic efficacy in a variety of animal models, affecting multiple organ systems, which supports its designation as a "broad-spectrum" antifibrotic agent.[3]

• Pulmonary Fibrosis: AK3280 is described as a potent inhibitor of fibrosis in animal models of pulmonary fibrosis.[7] While some related documents discuss pirfenidone combinations or other N-arylpyridone compounds (like AKEX0011 for silicosis [21]), the structural similarity of AK3280 (phenyl pyridone scaffold [7]) makes these findings contextually relevant to its potential in lung fibrosis.
• Hepatic Fibrosis: The compound has shown potent inhibitory effects in animal models of liver fibrosis.[3]
• Cardiac Fibrosis: Preclinical data indicate antifibrotic effects in cardiac models.[3] Specifically, AK3280, potentially through inhibition of the ASK1-p38 MAPK pathway, was shown to attenuate Angiotensin II-induced cardiac fibrosis in mice.[24]
• Skin Fibrosis: Antifibrotic activity has also been observed in animal models of skin fibrosis.[3]

The consistent description of AK3280 as "orally bioavailable" [3] alongside its efficacy in skin fibrosis models is noteworthy. The provided research does not consistently specify whether the effects observed in skin fibrosis models were achieved through systemic (e.g., oral) administration, which would indicate good skin penetration, or via unmentioned topical application. This lack of clarity is relevant given the user's query about an "AK3280 Cream." If skin efficacy was achieved orally, it would underscore the drug's systemic distribution and broad action. If topical administration was used in these preclinical skin models (though not explicitly stated), it might offer a rationale for exploring such a formulation, even if it's not the current focus of clinical development.

B. Pharmacodynamic Effects in Preclinical Studies

In cell-based assays, AK3280 demonstrated the ability to inhibit the expression of key fibrotic genes, including those for various collagen types (Col1a1, Col1a2, Col3a1) and alpha-smooth muscle actin (Acta2), a marker of myofibroblast activation. This inhibition was observed against induction by pro-fibrotic stimuli such as TGF-β, LPA, and serum.[24] In a mouse model of silicosis, AK3280 (as GDC-3280) was shown to inhibit the ASK1-p38 MAPK signaling pathway, which correlated with its anti-inflammatory and antifibrotic effects.[24]

C. Preclinical Tolerability

A significant aspect highlighted in preclinical data is the favorable tolerability profile of AK3280. It is reported to lack the gastrointestinal tolerability issues and other toxicities that are commonly associated with existing IPF therapies like pirfenidone.[1] This improved preclinical safety profile was a key driver for its advancement into clinical trials.

Table 2: Summary of Preclinical Studies of AK3280 in Fibrosis Models

Fibrotic Disease Model Example	Animal Species	Key Efficacy Findings	MOA Insights from Model	Route of Administration (in model, if specified)	Snippet ID(s)
Pulmonary Fibrosis (General)	Animal models	Potent fibrosis inhibitor	Modulation of fibrotic pathways	Oral (implied by "orally bioavailable" general statements)	7
Silicosis (Pulmonary Fibrosis)	Mouse	Alleviated inflammation and fibrosis	Inhibition of ASK1-p38 MAPK pathway, macrophage polarization regulation	Not specified in 29 (but GDC-3280 described as orally active)	24
Hepatic Fibrosis	Animal models	Potent fibrosis inhibitor	Broad antifibrotic activity	Oral (implied)	3
Cardiac Fibrosis (Ang II-induced)	Mouse	Attenuated cardiac fibrosis, improved cardiac function	Inhibition of ASK1-p38 MAPK pathway, attenuated upregulation of fibrosis and TGF-β expression	Not specified in 24 (but AK3280 described as orally available)	3
Skin Fibrosis	Animal models	Demonstrated antifibrotic effects	Broad antifibrotic activity	Not specified (but AK3280 described as orally bioavailable)	3

This table summarizes the breadth of AK3280's preclinical antifibrotic activity. The consistent finding of oral bioavailability across mentions, even when discussing efficacy in skin models, suggests systemic administration was likely used or at least is the primary characteristic. The absence of explicit mention of topical administration in these skin models is important context for the "cream" query.

V. Pharmacokinetics (PK)

A. Human Pharmacokinetics

Data on human pharmacokinetics primarily stem from Phase I studies, largely involving the GDC-3280 compound in healthy volunteers, which ArkBio subsequently licensed and advanced as AK3280.[13]

• Absorption: AK3280 is an orally available small molecule.[7] Following oral administration, it is generally readily absorbed, with a median time to maximum plasma concentration (tmax​) of less than 4.0 hours under various conditions.[13]
• Food Effect: A significant food effect has been observed. Administration of single doses of GDC-3280 (400 mg and 800 mg) after a meal resulted in statistically significant increases in systemic exposure (AUC), attributed to increased rates of absorption compared to the fasted state. This finding supports the recommendation for administering AK3280 with food in clinical settings to enhance bioavailability and/or consistency of exposure.[13]
• Distribution: Specific details on tissue distribution in humans are not extensively provided in the available snippets. However, its demonstrated efficacy in preclinical models of fibrosis affecting multiple organs (lung, liver, heart, skin) suggests systemic distribution following oral administration.[3]
• Metabolism: Detailed information regarding the metabolic pathways of AK3280 in humans is not extensively covered in the provided materials.
• Excretion: Renal excretion appears to be a major route of elimination for AK3280. In Phase I studies with GDC-3280, at single doses of 200 mg or lower, a substantial portion (more than 50-70%) of the orally administered dose was recovered in the urine as unchanged parent drug.[13]
• Half-life: Following repeat oral dose administration, steady-state plasma concentrations of GDC-3280 were achieved within 2 days. The apparent terminal half-life (t1/2​) was determined to be between 5 and 6 hours.[13]
• Dose Proportionality: The pharmacokinetic profile showed some dose dependency. In single ascending dose studies (Part A of Phase I), less-than-dose-proportional increases in systemic exposure were observed. However, in multiple ascending dose studies (Part B of Phase I), dose-proportional increases in exposure were noted within the tested dose range (200 mg or 275 mg BID; 525 mg QD).[13]
• Drug-Drug Interactions (DDI): Co-administration of GDC-3280 with rabeprazole, a proton pump inhibitor (PPI), led to decreased systemic exposure to GDC-3280, indicating a weak drug-drug interaction. This suggests that gastric pH may influence the absorption of AK3280.[13]
• Dosing Regimen Considerations: While early communications from ArkBio suggested that once-daily (QD) dosing might be feasible based on animal and healthy volunteer PK data [7], the successful Phase II IPF clinical trial employed a twice-daily (BID) dosing regimen.[1] This evolution likely reflects an optimization process to achieve sustained therapeutic concentrations or to balance efficacy and tolerability. The observed food effect and the potential interaction with PPIs are important considerations for consistent dosing and patient management.

B. Preclinical Pharmacokinetics

AK3280 was specifically designed to possess improved pharmacokinetic properties compared to its parent compound, pirfenidone.[1] It demonstrated oral bioavailability in various animal models, consistent with its intended route of administration in humans.[3]

VI. Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)

The clinical development of AK3280 for IPF has progressed through Phase I and Phase II studies, with positive results paving the way for Phase III investigation.

A. Phase I Clinical Trials

• GDC-3280 (Genentech): The initial Phase I development was conducted by Genentech under the code GDC-3280.
• A key study was NCT02471859 (also known as GB29751; EudraCT2015-000560-33). This was a randomized, double-blind, placebo-controlled, ascending single- and multiple-oral-dose trial in healthy volunteers conducted in the UK. The study assessed the safety, tolerability, and pharmacokinetics of GDC-3280. Single doses ranged from 25 mg to 1600 mg. Multiple-dose regimens included 200 mg or 275 mg BID, and 525 mg QD, administered for 7 days.[13]
• Key Findings: GDC-3280 was generally well tolerated. The majority of treatment-emergent adverse events (TEAEs) were mild, with headache and nausea being the most frequent with single doses, and nausea, dizziness, nasal congestion, and cough with multiple doses. Notably, no deaths, serious adverse events (SAEs), or dose-limiting toxicities (DLTs) were reported. Transient, treatment-related increases in serum creatinine (12-18% from baseline with single doses >400mg; 20-34% with multiple doses) were observed but were not considered DLTs. The pharmacokinetic profile supported twice-daily oral administration, preferably with food, for future trials.[13]
• AK3280 (Ark Biosciences): Following the licensing from Roche/Genentech, Ark Biosciences continued development under the AK3280 designation.
• ArkBio has referred to "Previous Phase I studies" demonstrating favorable safety, tolerability, and human PK profiles, likely encompassing or building upon the Genentech data.[1] Reports from January 2020 mentioned the successful completion of two clinical trials in humans, confirming excellent safety and tolerability without the typical side effects of existing IPF standard-of-care treatments.[7]
• A Phase I trial (NCT03990688) was planned by Ark Biosciences for IPF in healthy volunteers in Sweden (oral tablet), scheduled to start in August 2019.[25] The status and results of this specific trial are not detailed in subsequent snippets.

B. Phase II Clinical Trial in IPF (Ark Biosciences, China)

A pivotal Phase II proof-of-concept study of AK3280 in IPF patients has been completed in China, yielding positive top-line results announced in May 2025.[1]

• Trial Identifier: While not consistently stated in all press releases, this study is likely NCT05424887, also referred to by ArkBio as study AK3280-2002.[12]
• Study Design: This was a multicenter (31 clinical sites in China), randomized, double-blind, placebo-controlled study. It involved a 24-week treatment period, followed by a 24-week open-label extension phase.[1]
• Principal Investigator: The study was led by Professor Huaping Dai of the Department of Pulmonary and Critical Care Medicine at China-Japan Friendship Hospital, Beijing.[1]
• Patient Population: The trial enrolled patients in China diagnosed with IPF. Key eligibility criteria included age ≥40 and ≤80 years, FVC ≥45% of predicted value, DLco ≥30% of predicted value, and a 6-minute walk test (6MWT) distance of ≥100 meters without auxiliary support. Detailed inclusion and exclusion criteria are outlined in source.[20]
• Intervention: Participants were randomized to receive AK3280 at doses of 100 mg, 200 mg, 300 mg, or 400 mg, administered twice daily (BID), or placebo, for 24 weeks.[1]
• Efficacy Endpoints and Results:
• The primary endpoints focused on safety and tolerability.
• Secondary and clinical efficacy endpoints included changes in Forced Vital Capacity (FVC and % predicted FVC - %pFVC), Diffusing Capacity of the Lung for Carbon Monoxide (DLco), the 6-Minute Walk Test (6MWT), and patient-reported outcomes via the St. George's Respiratory Questionnaire (SGRQ) scores.[1]
• FVC and %pFVC: The high-dose groups of AK3280 demonstrated a notable improvement in FVC from baseline. Specifically, the 400 mg BID group exhibited:
• An absolute increase in FVC of +209.4 mL from baseline over 24 weeks.[1]
• A 6.4% adjusted improvement in %pFVC from baseline.[1]
• These improvements in FVC and %pFVC in the 400 mg BID group were statistically significant compared to the placebo group (p=0.002 and p=0.004, respectively).[1] This finding is particularly significant as current IPF therapies primarily slow FVC decline, whereas AK3280 showed an absolute increase.
• Other Lung Function and QoL Measures: Reports indicated that "Other lung and respiratory functions have also got better" [1], implying positive trends in DLco and 6MWT. Professor Huaping Dai also commented on "substantial symptom relief and benefits to quality-of-life in the IPF patients," suggesting improvements in SGRQ scores.[2]
• Safety and Tolerability in IPF Patients (Phase II):
• AK3280 exhibited a good safety and tolerability profile across all tested dose groups (100 mg to 400 mg BID).[1]
• A key differentiating feature was the absence of the gastrointestinal intolerability issues that are commonly associated with current standard-of-care IPF therapeutics like pirfenidone and nintedanib.[1] This favorable tolerability is considered crucial for long-term patient adherence and management in a chronic disease like IPF.[2]

The statistically significant improvement in absolute FVC, rather than merely a reduction in the rate of decline, observed in the Phase II study of AK3280 is a pivotal finding. If replicated in Phase III trials, this could represent a paradigm shift in IPF treatment, offering patients not just a slowing of progression but a potential for actual lung function improvement. This, combined with its superior reported tolerability (especially the lack of GI issues), positions AK3280 as a highly promising candidate.

C. Phase III Clinical Trial Plans

Following the positive outcomes from the Phase II proof-of-concept study, Ark Biosciences has announced that preparations are underway to initiate a pivotal Phase III clinical study for AK3280 in IPF.[2] As of May 2025, one source indicated that a Phase III trial for IPF is in the "Planning" status, with a focus on registrational approval and therapeutic use.[22]

Table 3: Summary of AK3280 Phase II IPF Clinical Trial (Presumed NCT05424887 / AK3280-2002) Design and Key Outcomes

Parameter	Details	Snippet ID(s)
Trial Identifier(s)	Likely NCT05424887 (AK3280-2002)	12
Phase	II (Proof-of-Concept)	1
Design	Randomized, double-blind, placebo-controlled, multicenter	1
Patient Population	Idiopathic Pulmonary Fibrosis (IPF) patients in China	1
Number of Sites	31	1
Treatment Arms/Doses	AK3280 (100mg, 200mg, 300mg, or 400mg BID) or Placebo	1
Treatment Duration	24 weeks (followed by 24-week open-label extension)	1
Primary Endpoints	Safety and tolerability	1
Key Secondary Efficacy Endpoints	FVC, %pFVC, DLco, 6MWT, SGRQ	1
FVC Change from Baseline (400mg BID vs. Placebo)	+209.4 mL (statistically significant, p=0.002)	1
%pFVC Change from Baseline (400mg BID vs. Placebo)	+6.4% adjusted improvement (statistically significant, p=0.004)	1
Key Safety Findings	Good safety and tolerability profile; Notably without gastrointestinal intolerability issues associated with current IPF therapeutics.	1

This table effectively summarizes the critical elements of the Phase II IPF trial, highlighting the promising efficacy signals—particularly the absolute FVC increase—and the favorable safety profile that are driving AK3280 towards Phase III development.

VII. Other Potential Indications

The broad-spectrum antifibrotic activity of AK3280 observed in preclinical models suggests its therapeutic potential may extend beyond IPF.

A. Based on Preclinical Data

• AK3280 has demonstrated antifibrotic effects in animal models of pulmonary, hepatic, cardiac, and skin fibrosis. This suggests a potential for AK3280 to be a clinically beneficial therapy for a range of fibrotic diseases affecting these organs.[3]
• Skin Fibrosis/Cicatrix:
• Preclinical efficacy in animal models of skin fibrosis has been reported.[3]
• One database lists "Cicatrix" and "Cicatrix, Hypertrophic" as inactive indications for AK-3280.[16] This might imply that while the potential was recognized, active development for these specific skin conditions (particularly via a topical route) is not currently prioritized or has been discontinued.
• The preclinical efficacy in skin models is the most plausible link to the user's query about an "AK3280 Cream." However, as previously discussed, the provided documentation does not confirm the development of such a formulation. The primary development pathway for AK3280 is clearly oral for systemic fibrotic diseases. The lack of specific information on the route of administration in these preclinical skin studies (i.e., whether topical or systemic) makes it difficult to draw firm conclusions about the viability or pursuit of a cream formulation based solely on these snippets.
• Silicosis:
• GDC-3280 (an alias of AK3280, also referred to as AK3287 or AKEX0011), described as an orally active compound based on pirfenidone's phenyl pyridone scaffold, demonstrated anti-inflammatory and anti-fibrotic effects in a mouse model of silicosis. This effect was linked to the inhibition of the ASK1-p38 MAPK pathway.[29] AKEX0011 is also characterized as a novel N-arylpyridone compound.[21] This suggests a potential therapeutic avenue for other interstitial lung diseases characterized by inflammation and fibrosis.

The broad preclinical antifibrotic profile is a strong asset for AK3280. However, the transition from preclinical findings in diverse models to active clinical development for multiple indications is a complex process influenced by strategic priorities, resource allocation, and the specific characteristics of the drug (such as its suitability for different routes of administration). Currently, the clinical development pipeline, as reflected in the provided information, is predominantly focused on oral AK3280 for IPF.

VIII. Safety and Tolerability Profile (Consolidated)

The safety and tolerability profile of AK3280 is a key aspect of its development, particularly in comparison to existing IPF therapies.

A. Healthy Volunteer Studies (Phase I - GDC-3280/AK3280)

Phase I studies in healthy volunteers indicated that AK3280 (as GDC-3280) was generally well tolerated across a range of single oral doses (up to 1600 mg) and multiple oral doses (up to 275 mg BID or 525 mg QD for 7 days).[7]

• The most frequently reported TEAEs were mild and included headache, nausea (more common with single doses), dizziness, nasal congestion, and cough (more common with multiple doses).[13]
• Importantly, no deaths, SAEs, or DLTs were reported in these healthy volunteer studies.[13]
• Transient, treatment-related increases in serum creatinine were observed at single doses greater than 400 mg (12-18% from baseline) and after multiple doses in all cohorts (20-34% from baseline). These were not classified as DLTs.[13]
• TEAEs were reported to occur more frequently when GDC-3280 was administered with food; however, food also increased drug absorption.[13]

B. IPF Patient Studies (Phase II - AK3280)

The Phase II proof-of-concept study in IPF patients further substantiated the favorable safety and tolerability of AK3280.[1]

• AK3280 demonstrated a good safety and tolerability profile across all tested dose groups (100 mg to 400 mg BID).[1]
• A significant finding was the reported absence of the gastrointestinal intolerability issues (such as nausea, diarrhea, and dyspepsia) that are commonly associated with current IPF therapeutics like pirfenidone and nintedanib. This was highlighted as a key advantage.[1]
• This favorable tolerability profile is considered essential for the long-term management of IPF patients, potentially leading to better treatment adherence and sustained therapeutic benefit.[2]

C. Preclinical Safety

Preclinical data also suggested that AK3280 was designed to avoid the gastrointestinal tolerability issues and other toxicities associated with existing IPF drugs.[1]

The consistent reporting of good tolerability, especially the lack of significant GI side effects, positions AK3280 as a potentially more patient-friendly option for the chronic management of IPF. If these safety advantages are maintained in Phase III trials and post-marketing, they could significantly impact patient compliance and overall treatment success compared to current standards of care.

IX. Regulatory Status

A. Current Development Phase

• Idiopathic Pulmonary Fibrosis (IPF):
• Phase II clinical development for IPF is complete, with positive top-line results announced by ArkBio in May 2025.[1]
• AK3280 is currently advancing to Phase III clinical trials for IPF. ArkBio is in the planning and preparation stages for these pivotal studies.[2] One source lists a Phase III trial for IPF as being in the "Planning" status as of May 2025, with a focus on registrational approval and therapeutic use.[22]
• Other Indications:
• "Cicatrix" and "Cicatrix, Hypertrophic" are listed as inactive indications for AK-3280 in one database.[16] No active clinical development for these or other fibrotic conditions (hepatic, cardiac, skin fibrosis) is detailed in the provided snippets, despite positive preclinical findings.

B. Orphan Drug Designation

• According to available database information, AK3280 (under its various codes) does not currently hold Orphan Drug Designation in key regulatory regions like the US (FDA) or Europe (EMA) for IPF or other indications.[18]
• Searches of FDA and EMA orphan drug databases using general terms did not yield specific results for AK3280.[31]
• The absence of orphan drug status for an IPF candidate is notable, as IPF often qualifies for such designations. This could be due to various factors, including strategic decisions by the developer, regional prevalence considerations, or the timing of applications relative to the perceived clinical benefit over existing therapies. The promising Phase II data showing FVC improvement might strengthen a future application if pursued.

C. Approvals

• AK3280 is an investigational drug and has not received marketing approval from the FDA, EMA, or other major regulatory authorities for any indication, based on the provided information.[35]

X. Discussion

A. Summary of AK3280's Profile

AK3280 is an orally administered, next-generation small molecule antifibrotic agent, meticulously optimized from the existing IPF drug pirfenidone. Its development is primarily focused on treating Idiopathic Pulmonary Fibrosis. The most compelling evidence for its potential comes from a recently completed Phase II clinical trial in IPF patients in China. This study reported statistically significant improvements in Forced Vital Capacity (FVC), with the 400mg BID dose showing an absolute increase in FVC from baseline, a notable departure from current therapies that primarily slow FVC decline. Furthermore, AK3280 demonstrated a favorable safety and tolerability profile, particularly a lack of the gastrointestinal side effects that often limit the use of pirfenidone and nintedanib. Preclinical studies also support its broad antifibrotic activity in models of lung, liver, heart, and skin fibrosis, and suggest a mechanism involving modulation of TGF-β and LPA-induced fibrotic pathways, potentially via inhibition of the ASK1-p38 MAPK signaling cascade.

B. Re-addressing "AK3280 Cream"

Based on a comprehensive analysis of the provided research material, there is no direct evidence to support the current clinical development or existence of an "AK3280 Cream" formulation. The overwhelming majority of data points to AK3280 as an orally administered drug for systemic fibrotic conditions, with IPF as the lead indication.

While preclinical studies have shown that AK3280 possesses antifibrotic activity in animal models of skin fibrosis 3, the route of administration in these specific studies is not consistently clarified. Given AK3280's established oral bioavailability 3 and the systemic nature of its primary development focus, it is plausible that these skin effects were observed after systemic administration. The listing of "Cicatrix" as an inactive indication 16 suggests that skin applications might have been considered at some point, but there is no current data in the provided snippets to indicate active development of a topical or cream formulation. Therefore, the report focuses on the well-documented oral development of AK3280.

C. Strengths of AK3280

The development program for AK3280 highlights several potential strengths:

1. Potentially Superior Efficacy in IPF: The Phase II data suggesting an improvement in absolute FVC, rather than just a slowing of decline, is a significant potential advantage over existing IPF therapies.[1] If this is confirmed in Phase III, it could represent a major advancement in IPF treatment.
2. Improved Tolerability Profile: The consistent reports of good safety and, crucially, the absence of significant gastrointestinal intolerability [1], address a major limitation of current IPF drugs. This could lead to better patient adherence, sustained dosing, and improved quality of life.
3. Broad-Spectrum Antifibrotic Potential: Extensive preclinical data showing efficacy in models of pulmonary, hepatic, cardiac, and skin fibrosis suggest that AK3280 might have therapeutic applications beyond IPF.[3]
4. Clear Development Path: With positive Phase II results for IPF, ArkBio is actively preparing for pivotal Phase III studies, indicating a clear regulatory and clinical progression.[2]
5. Optimized Pharmacokinetics: AK3280 was designed for improved PK properties over pirfenidone, with human Phase I data supporting oral administration, potentially with food, and an acceptable half-life for BID dosing.[7]

D. Limitations and Unanswered Questions from Available Data

Despite the promising data, several aspects require further clarification or are limitations of the currently available information:

1. Comprehensive Phase II IPF Data: While top-line FVC results are positive, full, peer-reviewed publication of the Phase II IPF trial, including detailed statistical analyses for all endpoints (DLco, 6MWT, SGRQ, biomarker changes) and subgroup analyses, is awaited.
2. Long-Term Efficacy and Safety: Data from the 24-week open-label extension of the Phase II study, and ultimately from longer-term Phase III trials, will be essential to confirm sustained efficacy and long-term safety.
3. Definitive Molecular Advantages: While optimized from pirfenidone and potentially targeting the ASK1-p38 MAPK pathway, a more detailed elucidation of the precise molecular mechanisms that confer its enhanced efficacy and improved tolerability would be beneficial.
4. Chemical Identity Clarification: The discrepancy in reported CAS numbers and molecular formulas for AK3280/GDC-3280 needs definitive resolution from primary sources or regulatory filings to ensure unambiguous identification.
5. Development for Other Indications: Despite strong preclinical rationale for other fibrotic conditions, there is limited information on active clinical development programs for AK3280 beyond IPF.
6. Regulatory Designations: Information on specific regulatory designations beyond the reported lack of orphan status (e.g., Fast Track, Breakthrough Therapy from FDA/EMA) is not detailed in the snippets.

E. Future Research Directions

The future development of AK3280 will likely focus on:

1. Pivotal Phase III Trials for IPF: Successful completion and positive results from these trials are paramount for regulatory approval.
2. Further Mechanistic Studies: Deeper investigation into its molecular targets and pathways to fully understand its advantages over pirfenidone and its broad antifibrotic effects.
3. Exploration in Other Fibrotic Diseases: Depending on Phase III IPF outcomes and strategic priorities, clinical trials in other fibrotic conditions (e.g., liver fibrosis, scleroderma-related skin fibrosis) could be initiated, leveraging its oral bioavailability and broad preclinical efficacy.
4. Long-term Observational Studies: Post-approval, long-term studies will be important to monitor real-world effectiveness and safety.

F. Potential Impact on IPF Treatment Landscape

If the promising efficacy (FVC improvement) and enhanced tolerability (particularly GI safety) of AK3280 are confirmed in Phase III trials, it has the potential to significantly alter the treatment landscape for IPF. Current therapies primarily aim to slow disease progression. A treatment that could offer a degree of lung function improvement, coupled with a more manageable side-effect profile, would be a substantial step forward. This could lead to AK3280 becoming a new standard of care, potentially as a first-line option or for patients intolerant to existing therapies, thereby improving not only progression rates but also patient quality of life and long-term outcomes more profoundly than currently possible.

XI. Conclusion

AK3280 is an investigational, orally administered, next-generation antifibrotic agent that has demonstrated considerable promise in the treatment of Idiopathic Pulmonary Fibrosis. Optimized from pirfenidone, it aims to provide enhanced efficacy and superior tolerability. Phase II clinical trial results in IPF patients are particularly encouraging, highlighted by a statistically significant improvement in absolute Forced Vital Capacity from baseline, a distinct advantage over current therapies that primarily slow FVC decline. Furthermore, AK3280 has shown a favorable safety profile in these trials, notably lacking the gastrointestinal side effects common with existing IPF treatments.

Preclinical studies indicate broad antifibrotic activity across multiple organ systems, including the lungs, liver, heart, and skin, suggesting a wider therapeutic potential. The mechanism of action appears to involve modulation of key fibrotic pathways, including those driven by TGF-β and LPA, and potentially specific inhibition of the ASK1-p38 MAPK pathway.

Regarding the query for "AK3280 Cream," the comprehensive review of the provided research materials does not yield evidence of an active clinical development program for a topical cream formulation of AK3280. While preclinical efficacy in skin fibrosis models has been noted, the primary development focus remains an oral formulation for systemic fibrotic diseases, led by IPF.

The successful completion of the Phase II IPF trial has paved the way for pivotal Phase III studies. The outcomes of these larger, longer-term trials will be crucial in definitively establishing the clinical benefit and safety of AK3280 and determining its ultimate role in the management of IPF and potentially other debilitating fibrotic conditions. If the Phase II findings are replicated, AK3280 could represent a significant therapeutic advancement for patients suffering from IPF.

Works cited

1. ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF), accessed May 26, 2025, https://www.arkbiosciences.com/80/103
2. ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire, accessed May 26, 2025, https://www.prnewswire.com/news-releases/arkbio-announces-positive-phase-ii-results-of-ak3280-for-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302456469.html
3. Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models - PubMed, accessed May 26, 2025, https://pubmed.ncbi.nlm.nih.gov/40015207/
4. ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire, accessed May 26, 2025, https://www.prnewswire.com/apac/news-releases/arkbio-announces-positive-phase-ii-results-of-ak3280-for-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302456466.html
5. ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Pipelinereview, accessed May 26, 2025, https://pipelinereview.com/arkbio-announces-positive-phase-ii-results-of-ak3280-for-treatment-of-idiopathic-pulmonary-fibrosis-ipf/
6. About ArkBio, accessed May 26, 2025, https://www.arkbiosciences.com/en
7. Ark Biosciences to Present at JPM Healthcare Conference in San Francisco - Business Wire, accessed May 26, 2025, https://www.businesswire.com/news/home/20200107005475/en/Ark-Biosciences-to-Present-at-JPM-Healthcare-Conference-in-San-Francisco
8. Pulmonary Fibrosis Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism Of Action, ROA, NDA, IND, And Companies - Barchart.com, accessed May 26, 2025, https://www.barchart.com/story/news/31795387/pulmonary-fibrosis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies
9. ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment - PR Newswire, accessed May 26, 2025, https://www.prnewswire.com/apac/news-releases/arkbio-presented-at-the-8th-annual-ipf-summit-and-announced-completion-of-patient-enrollment-for-phase-2-clinical-trial-of-ak3280-a-next-generation-drug-for-ipf-treatment-302230353.html
10. Shanghai Ark Biopharmaceutical Announces Strategic Collaboration with Partex for Partnership and Out-Licensing of Phase 1 Autotaxin Inhibitor AK0707, accessed May 26, 2025, https://www.arkbiosciences.com/80/96
11. Pulmonary Fibrosis Pipeline Insight - DelveInsight, accessed May 26, 2025, https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight
12. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) - Taylor & Francis Online, accessed May 26, 2025, https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2396121
13. A phase 1, randomized study to evaluate safety, tolerability, and ..., accessed May 26, 2025, https://pubmed.ncbi.nlm.nih.gov/34166834/
14. Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema - Dermatology Times, accessed May 26, 2025, https://www.dermatologytimes.com/view/late-breaking-data-long-term-safety-and-efficacy-of-delgocitinib-cream-for-chronic-hand-eczema
15. A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus | MedPath, accessed May 26, 2025, https://trial.medpath.com/clinical-trial/cf6e1d161bf0f277/nct02565134-multi-center-double-blind-randomized-placebo-controlled-pac-14028-cream
16. GDC-3280 - Drug Targets, Indications, Patents - Synapse, accessed May 26, 2025, https://synapse.patsnap.com/drug/60800b8939484e04b1f1b18fb9af4314
17. ArkBio's investigational lung fibrosis drug shows promise in mid-stage study, accessed May 26, 2025, https://firstwordpharma.com/story/5962261
18. AK 3280 - AdisInsight, accessed May 26, 2025, https://adisinsight.springer.com/drugs/800042726
19. ArkBio Reports P-II Study Data Evaluating AK3280 to Treat Idiopathic Pulmonary Fibrosis (IPF) - PharmaShots, accessed May 26, 2025, https://pharmashots.com/23078/arkbio-reports-p-ii-study-data-evaluating-ak3280-to-treat-idiopathic-pulmonary-fibrosis-ipf/
20. A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis - GoodDay, accessed May 26, 2025, https://dev-multi-sponsor-trials.xogene.com/trials/5424887
21. Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models | Request PDF - ResearchGate, accessed May 26, 2025, https://www.researchgate.net/publication/389429529_Broad_antifibrotic_activities_of_AK3280_in_pulmonary_hepatic_cardiac_and_skin_fibrosis_animal_models
22. A phase 3 pivotal trial of AK3280 in patients with idiopathic pulmonary fibrosis (IPF), accessed May 26, 2025, https://adisinsight.springer.com/trials/700382754
23. Bayer starts Phase I study with GIRK4 inhibitor for treatment of patients with atrial fibrillation, accessed May 26, 2025, https://pipelinereview.com/bayer-starts-phase-i-study-with-girk4-inhibitor-for-treatment-of-patients-with-atrial-fibrillation/
24. www.probechem.com, accessed May 26, 2025, https://www.probechem.com/userfiles/Products/PDF/PC-72631/PC-7263101/PC-7263101_DataSheet.pdf
25. AK 3280 - New Drug Approvals, accessed May 26, 2025, https://newdrugapprovals.org/2019/08/16/ak-3280/
26. idiopathic pulmonary fibrosis - New Drug Approvals, accessed May 26, 2025, https://newdrugapprovals.org/category/idiopathic-pulmonary-fibrosis/
27. clinicaltrials.gov, accessed May 26, 2025, https://clinicaltrials.gov/study/NCT05424887
28. accessed January 1, 1970, https://www.arkbiosciences.com/news/info/103
29. GDC-3280 (AK3287) | Anti-inflammatory/Anti-fibrotic Agent | MedChemExpress, accessed May 26, 2025, https://www.medchemexpress.com/ak3287.html
30. GDC-3280 (AK3280) | CAS 1590403-33-0 - AbMole BioScience, accessed May 26, 2025, https://www.abmole.com/products/gdc-3280.html
31. Orphan designation: Overview | European Medicines Agency (EMA), accessed May 26, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
32. EU/3/24/2937 - orphan designation for treatment of acute myeloid leukaemia, accessed May 26, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2937
33. accessed January 1, 1970, https://www.ema.europa.eu/en/medicines/search_medicines
34. Search Orphan Drug Designations and Approvals, accessed May 26, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
35. Iovance Biotherapeutics, Inc. to Report First Quarter 2025 Financial Results and Corporate Updates on May 8, 2025 - Moomoo, accessed May 26, 2025, https://www.moomoo.com/news/post/52505132/iovance-biotherapeutics-inc-to-report-first-quarter-2025-financial-results